阿西米尼临床药理学综述
阿西米尼是首个靶向BCR::ABL1肉豆蔻酰口袋的变构抑制剂,获批每日总剂量80 mg用于对≥2种酪氨酸激酶抑制剂耐药或不耐受的慢性期慢性髓性白血病成人患者,T315I突变者200 mg每日两次。本综述总结其药代动力学与药效学数据,绝对生物利用度约73%,需空腹给药,主要经CYP3A4氧化和UGT介导的葡萄糖醛酸化代谢,体重、年龄、性别、种族及肝肾功能损害对PK无实质影响,暴露-疗效与暴露-安全性模型支持其临床开发与监管申请。
要点
- 空腹服用,高脂餐降低暴露;80 mg每日一次或200 mg每日两次(T315I突变)。
- 清除率6.31 L/h,表观终末半衰期7–15 h,血浆蛋白结合率97.3%。
- 肝肾功能损害、体重、年龄、性别、种族对PK无实质影响。
核心结论
- 阿西米尼的临床药理学特征支持其用于耐药或不耐受慢性期慢性髓性白血病及T315I突变患者的获批适应症。
研究设计与样本
- 本综述汇总阿西米尼的PK和PD数据,包括临床与预测的药物相互作用研究及暴露-反应模型。
主要发现
- 绝对生物利用度约73%,清除率6.31 L/h,分布容积111 L,血浆蛋白结合率97.3%,表观终末半衰期7–15 h。
- 主要经CYP3A4氧化(36.0%)及UGT2B7(13.3%)和UGT2B17(7.8%)葡萄糖醛酸化代谢,BCRP介导的胆汁分泌约占系统清除31.1%。
- 体重、年龄、性别、种族及肾或肝损害对PK无实质影响。
- 无T315I突变患者暴露-疗效呈轻微正相关但无临床意义,T315I突变患者需要更高暴露才能达到疗效。
- 在所研究的广泛暴露或剂量范围内,暴露与关注的不良事件无 apparent 关联,且对心脏复极无临床相关影响。
关键数值与推荐
- 获批剂量:每日总剂量80 mg用于对≥2种TKI耐药或不耐受的慢性期CML成人患者;T315I突变者200 mg每日两次。
- 需空腹给药,因为食物(尤其高脂餐)降低暴露。
临床怎么用
- 临床用药应空腹服用阿西米尼,并依据是否携带T315I突变选择80 mg每日一次或200 mg每日两次方案。
- 无需根据体重、年龄、性别、种族或肝肾功能损害进行剂量调整。
局限性
- 本文为综述,未报告新的原始研究数据或样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asciminib is a first-in-class allosteric inhibitor of the kinase activity of BCR::ABL1, specifically targeting the ABL myristoyl pocket (STAMP). This review focuses on the pharmacokinetic (PK) and pharmacodynamic data of asciminib, which is approved at a total daily dose of 80 mg for the treatment of adult patients with chronic myeloid leukemia in chronic phase who are either resistant or intolerant to ≥ 2 tyrosine kinase inhibitors or those harboring the T315I mutation (at a dose of 200 mg twice daily). Asciminib is predicted to be almost completely absorbed from the gut, with an absolute bioavailability (F) of approximately 73%. It should be administered in a fasted state, as food (particularly high-fat meals) reduces exposure. Asciminib displays a slightly greater than dose-proportional increase in exposure, with no time-dependent changes in PK observed following repeated dosing. This drug shows low clearance (6.31 L/h), with a moderate volume of distribution (111 L) and high human plasma protein binding (97.3%). The apparent terminal elimination half-life (t1/2) across studies was estimated to be between 7 and 15 h. The PK of asciminib is not substantially affected by body weight, age, gender, race, or renal or hepatic impairment. Asciminib is primarily metabolized via CYP3A4-mediated oxidation (36.0%) and UGT2B7- and UGT2B17-mediated glucuronidation (13.3% and 7.8%, respectively); biliary secretion via breast cancer resistance protein contributes to about 31.1% to total systemic clearance, which is mainly through hepatic metabolism and biliary secretion through the fecal pathway, with renal excretion playing a minor role. The potential for PK drug interaction for asciminib both as a victim and a perpetrator has been summarized here based on clinical and predicted drug-drug interaction studies. Robust exposure-response models characterized asciminib exposure-efficacy and exposure-safety relationships. In patients without the T315I mutation, the exposure-efficacy analysis of the time course of BCR::ABL1IS percentages highlighted the existence of a slightly positive, albeit not clinically significant, relationship. Higher exposure was required for efficacy in patients harboring the T315I mutation compared with those who did not. The exposure-safety relationship analysis showed no apparent association between exposure and adverse events of interest over the broad range of exposure or dose levels investigated. Asciminib has also been shown to have no clinically relevant effect on cardiac repolarization. Here, we review the clinical pharmacology data available to date for asciminib that supported its clinical development program and regulatory applications.
引用
- Hoch M, Huth F, Manley PW, et al. Clinical Pharmacology of Asciminib: A Review. Clin Pharmacokinet. 2024. PMID: 39467980. doi:10.1007/s40262-024-01428-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。